Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
← catalyst calendarSponsored by ALK-Abelló A/S (industry) · ALK-B.CO — their whole pipeline →.
Phase
—
Status
Unknown status
Study type
Observational
Enrollment
100estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-21 | actual | When the study began enrolling |
| Primary completion | 2025-05-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-20 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Allergic Rhinitis Due to House Dust Mite
- Allergic Asthma
Intervention
- Drug: Standardised allergen extract from house dust mites — also filed as ACARIZAX® (12-SQ HDM)
Primary outcome
what the primary-completion date above is the date OFCorrelation between three measurement instruments
measured 12 months
Permalink · ALK-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed